2018-08-29T11:43:56-07:00 2017-12-31 204723636 ISLER CPA LLC 1976 GARDEN AVE EUGENE OR 97403 990 2017-01-01 930995453 FANCONI ANEMIA RESEARCH FUND INC FANC 5416874658 1801 WILLAMETTE STREET NO 200 EUGENE OR 97401 MARK PEARL VICE PRESIDENT 5416874658 2018-08-30 true GARY ISKRA P00051776 5413425161 2018-08-08 2017 2022-09-23 18:48:47Z MARK PEARL 1801 WILLAMETTE STREET NO 200 EUGENE OR 97401 3465927 false X WWW.FANCONI.ORG X TO FIND EFFECTIVE TREATMENTS AND A CURE FOR FANCONI ANEMIA AND TO PROVIDE EDUCATION AND SUPPORT SERVICES TO AFFECTED FAMILIES WORLDWIDE. 13 13 10 50 0 3096737 3262131 0 82382 122924 23495 80872 3202614 3465927 1940710 931559 0 579149 597718 0 300645 758909 983258 3278768 2512535 -76154 953392 7077435 7712637 1903126 1132939 5174309 6579698 TO FIND EFFECTIVE TREATMENTS AND A CURE FOR FANCONI ANEMIA AND TO PROVIDE EDUCATION AND SUPPORT SERVICES TO AFFECTED FAMILIES WORLDWIDE. false false 1578824 931559 SUPPORT OF RESEARCH INTO THE CAUSE AND CURE OF FANCONI ANEMIA 310338 PROVIDING EDUCATION AND SUPPORT TO FAMILIES AFFECTED BY FANCONI ANEMIA 1889162 true true false false false false false false false false false true false false false true true false false false false false false false false false false true false false false false false false false false false false true false false false false false false false false true 1 0 10 true false false false false false false false false false false X 13 13 false false false false false false false true true false false true true true true true true true true false AK AL AR CA CO CT DC FL GA HI IL KS KY MA MD ME MI MN MS NC ND NH NJ NM NY OH OK OR PA RI SC TN UT VA WA WI WV X X MARK QUINLAN 5416874658 1801 WILLAMETTE ST SUITE 200 EUGENE OR 97401 KEVIN MCQUEEN PRESIDENT 10.00 X X 0 0 0 MARK PEARL VICE PRESIDE 10.00 X X 0 0 0 SHARON SCHUMAN SECRETARY/TR 5.00 X X 0 0 0 ANDRE HESSELS TREASURER 10.00 X X 0 0 0 DAVID FIASCHETTI BOARD MEMBER 1.00 X 0 0 0 BRIAN HORRIGAN BOARD MEMBER 1.00 X 0 0 0 ORION MARX BOARD MEMBER 5.00 X 0 0 0 RACHEL ALTMANN BOARD MEMBER 1.00 X 0 0 0 STELLA M DAVIES BOARD MEMBER 1.00 X 0 0 0 LYNN FROHNMAYER BOARD MEMBER 10.00 X 0 0 0 BILL MCCOREY BOARD MEMBER 1.00 X 0 0 0 NANCY GOLDEN BOARD MEMBER 1.00 X 0 0 0 PETER PLESS BOARD MEMBER 1.00 X 0 0 0 MARK QUINLAN - AS OF 432017 EXECUTIVE DI 40.00 X 76394 0 2000 CYNTHIA PAPPAS-THROUGH 42117 EXECUTIVE DI 40.00 X 44173 0 2509 BRADLEY PRESTON SCIENCE DIRE 40.00 X 144600 0 0 265167 4509 1 false false false 3262131 114674 3262131 122924 122924 OTHER REVENUE 900099 80872 80872 80872 3465927 80872 122924 931559 931559 125076 102915 10054 12107 380743 169764 154488 56491 7252 7252 35195 24892 3593 6710 49452 29068 13021 7363 758 758 16330 16330 4021 472 30 3519 120508 43844 49382 27282 47635 26108 15162 6365 29324 21966 1472 5886 447442 412573 33599 1270 10836 5120 4321 1395 SUPPLIES 79764 23075 7425 49264 SPECIAL PROJECTS 65194 27639 376 37179 MISCELLANEOUS 48475 4541 3579 40355 RECRUITING 37630 20635 1600 15395 75341 44991 286 30064 2512535 1889162 322728 300645 184 140 1880379 1017890 2422 5196872 6692185 7077435 7712637 25483 19480 1877643 1113459 1903126 1132939 X 3684555 4816176 1489754 1763522 5174309 6579698 7077435 7712637 X 953392 362525 -28028 117500 X X false true X true false X 1870643 1719329 3378398 3096737 3262131 13327238 1870643 1719329 3378398 3096737 3262131 13327238 3219740 10107498 79452 35113 5693 82382 122924 325564 13652802 80872 0.74030 0.78080 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED INVESTMENTS - CDS & CASH SWEEP 2783475 F US EQUITIES 2380106 F TIPS BOND ETFS 980663 F INTERNATIONAL EQUITIES 547941 F 6692185 X 3800424 362525 362525 3437899 28028 28028 3465927 2395035 -117500 -117500 2512535 2512535 SCHEDULE D, PAGE 3, PART X FANCONI ANEMIA RESEARCH FUND, INC. IS EXEMPT FROM INCOME TAXES UNDER INTERNAL REVENUE CODE ("IRC") SECTION 501(C)(3) AND IS NOT A PRIVATE FOUNDATION WITHIN THE MEANING OF THE IRC AND AS AN ENTITY THAT QUALIFIES FOR DEDUCTIBLE CONTRIBUTIONS. ACCORDINGLY, NO PROVISION HAS BEEN MADE FOR INCOME TAXES IN THE FINANCIAL STATEMENTS. THE ORGANIZATION CONSIDERS ANY UNCERTAIN TAX POSITIONS CONSISTENT WITH GAAP. SCHEDULE D, PAGE 4, PART XII, LINE 2D PREVIOUSLY AWARDED GRANT TERMINATED -117,500 true STANFORD UNIVERSITY STANFORD UNIVERSITY LOCKBOX PO BOX 44253 SAN FRANCISCO CA 941144253 941156365 190940 PREVENT DNA DAMAGE BOSTON UNIVERSITY 300 LONGWOOD AVE BOSTON MA 021155724 042774441 175000 ENGINEER HEMATOP. SC YALE UNIVERSITY 25 SCIENCE PARK 150 MUNSON ST 3RD FLOOR NEW HAVEN CT 06520 060646973 112500 CORRECT FA PHENOTYPE BOSTON'S CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON MA 021155724 042774441 20000 METFORMIN PILOT STDY THE REGENTS OF THE UNIVERSITY OF CA 2195 HEARST AVE ROOM 130 UNIVERSITY OF CALIFORNIA BERKELEY CA 947201130 946002123 125600 TRCTBLE GENE EDITING DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BP 451 BOSTON MA 022155450 042263040 175000 PATHWAY INHIBITORS THE OHIO STATE UNIVERSITY 1960 KENNY RD COLUMBUS OH 432101016 316025986 122568 CANCER CHMOPREVENTN SCHEDULE I, PAGE 1, PART I, LINE 2 THE ORGANIZATION COMPILES A GRANT FILE FOR EACH GRANT RECIPIENT THAT HOUSES THE GRANT APPLICATION, REVIEWS CONDUCTED BY OUTSIDE REVIEWERS, THE PROPOSAL REVIEW COMMITTEE'S REPORT, A CV FOR ALL OF THOSE PARTICIPATING IN THE PROJECT AND A SIGNED ACCEPTANCE OF AWARD. THIS DOCUMENT MUST BE SIGNED BY THE PRINCIPAL INVESTIGATOR AND THE OFFICIAL SIGNING AUTHORITY OF THE INSTITUTION WHERE THE RESEARCH WILL BE PERFORMED. TO MONITOR THE USE OF FUNDS, FINANCIAL AND RESEARCH REPORTS ARE REQUIRED ON AN ANNUAL BASIS DURING THE LIFE OF THE GRANT AND REVIEWED BY THE DEPUTY DIRECTOR TO ENSURE FUNDS ARE BEING USED APPROPRIATELY IN ADDITION TO BEING REVIEWED BY THE PROPOSAL REVIEW COMMITTEE AND THE BOARD. SCHEDULE I, PAGE 4, PART IV FURTHER DETAIL ON PURPOSE OF GRANT/ASSISTANCE BY LINE: PART II, LINE 1 - THE PREVENTION OF DNA DAMAGE IN FANCONI ANEMIA HSC BY ALDH ACTIVATORS. PART II, LINE 2 - ENGINEERING FANCONI ANEMIA HEMATOPOIETIC STEM CELLS FOR HUMAN IPS CELLS. PART II, LINE 3 - USE OF TRIPLEX-FORMING PNAS AS A STRATEGY FOR CORRECTION OF THE FA PHENOTYPE. PART II, LINE 4 - PILOT STUDY OF METFORMIN FOR PATIENTS WITH FANCONI ANEMIA. PART II, LINE 5 - DEFINING TRACTABLE APPROACHES FOR GENE EDITING OF FANCONI ANEMIA HEMATOPOIETIC STEM CELLS. PART II, LINE 6 - TGF-B PATHWAY INHIBITORS FOR THE TREATMENT OF BONE MARROW FAILURE IN FA. PART II, LINE 7 - FIELD COVERAGE CANCER CHMOPREVENTION VIA JANUS NANOPARTICLES. X 6 114674 FAIR MARKET VALUE false true false SCHEDULE M, PAGE 2, PART II ALL NON-CASH CONTRIBUTIONS ARE REVIEWED AND DEPOSITED ONCE A MONTH BY THE FINANCE COORDINATOR, AND THEN ARE REVIEWED AGAIN DURING MONTH END CLOSING REPORT REVIEW BY THE EXECUTIVE DIRECTOR. FORM 990, PAGE 6, PART VI, LINE 11B THE 990 WILL BE PREPARED FOR A BOARD MEETING DURING THE YEAR AT WHICH TIME A FINAL DRAFT VERSION WILL BE SHARED WITH THE BOARD AND APPROVED BY VOTE PRIOR TO SUBMITTING THE 990 TO THE OFFICIALS. FORM 990, PAGE 6, PART VI, LINE 12C BOARD MEMBERS ANNUALLY STATE ANY REAL OR POTENTIAL CONFLICTS OF INTEREST ON A CONFLICT OF INTEREST DISCLOSURE FORM. FORM 990, PAGE 6, PART VI, LINE 15A NO INDEPENDENT REVIEW WAS CONDUCTED FOR THIS POSITION. WAGE FOR THIS POSITION IS SET BY THE BOARD PRESIDENT BY REVIEWING SELF- CONDUCTED MARKET RESEARCH. FORM 990, PAGE 6, PART VI, LINE 15B EMPLOYEE COMPENSATION WAS EVALUATED BY COLLECTING COMPARABLE DATA FROM NON- PROFIT, STATE, AND COUNTY SOURCES IN ADDITION TO WAGE ANALYSIS REVIEW BY INDEPENDENT PERSONS WHICH WAS THEN USED TO FORMULATE WAGES BY THE EXECUTIVE DIRECTOR AND APPROVED BY THE EXECUTIVE COMMITTEE BEFORE IMPLEMENTATION. FORM 990, PAGE 6, PART VI, LINE 17 MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSISSIPPI, NORTH CAROLINA, NORTH DAKOTA, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA FORM 990, PAGE 6, PART VI, LINE 19 WHEN GOVERNING DOCUMENTS OR THE CONFLICT OF INTEREST POLICY ARE REQUESTED, A COPY IS MADE AND MAILED TO THE REQUESTING PARTY. THE ANNUAL 990 AND AUDIT REPORT ARE ON THE ORGANIZATION'S WEBSITE AND COPIES ARE ALSO ISSUED WHEN REQUESTED. FORM 990, PART XI, LINE 9 TERMINATION OF PREV. AWARDED GRANTS 117,500 A PREVIOUSLY AWARDED PROGRAM GRANT WAS TERMINATED DUE TO THE GRANTEE NOT COMPLETING THE PROCESS IN WHICH WAS STATED IN THE PROPOSAL FOR THE GRANT. FORM 990, PAGE 12, PART XII, LINE 2C THE AUDIT OF THE FINANCIAL STATEMENTS WAS PREVIOUSLY OVERSEEN BY THE DEPUTY AND EXECUTIVE DIRECTORS. THE DEPUTY DIRECTOR'S POSITION WAS ELIMINATED IN JANUARY 2017. THE REVIEW PROCESS HAS CHANGED AS NOW THE REVIEW OF THE FINANCIAL STATEMENTS IS OVERSEEN ONLY BY THE EXECUTIVE DIRECTOR AND REVIEWED BY THE BOARD. THERE WAS NO CHANGE IN SELECTION OF THE INDEPENDENT ACCOUNTANT.